^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    eribulin mesylate

    i
    Other names: E7389, ER-086526, B1939 mesylate, B-1939, Halichondrin B analog, NSC-707389
    Company:
    Generic mfg.
    Drug class:
    Microtubule inhibitor
    Related drugs:
    7d
    Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Washington University School of Medicine | Trial primary completion date: Nov 2028 --> May 2031 | Trial completion date: Oct 2033 --> Apr 2036
    Trial completion date • Trial primary completion date
    |
    eribulin mesylate • zanzalintinib (XL092)
    13d
    Efficacy and safety of eribulin therapy for breast cancer with liver metastasis: a retrospective real-world study. (PubMed, Front Oncol)
    In this single-center retrospective exploratory analysis, eribulin-based therapy demonstrated preliminary activity in heavily pre-treated breast cancer patients with liver metastases. These hypothesis-generating findings warrant further prospective validation.
    Retrospective data • Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    eribulin mesylate
    14d
    Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> May 2027
    Trial completion date
    |
    ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog)
    |
    HER-2 amplification • HER-2 negative • PIK3CA mutation • PTEN mutation
    |
    eribulin mesylate • Aliqopa (copanlisib)
    15d
    YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P3, N=376, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    gemcitabine • capecitabine • eribulin mesylate • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy) • BNT326
    26d
    A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) (clinicaltrials.gov)
    P3, N=644, Active, not recruiting, AstraZeneca | Trial completion date: Nov 2028 --> Dec 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    PD-L1 expression • PD-L1 negative
    |
    carboplatin • capecitabine • albumin-bound paclitaxel • eribulin mesylate • Datroway (datopotamab deruxtecan-dlnk)
    1m
    Biomarkers in Spinal Metastasis of Breast Cancer: Insights Into Survival and Functional Outcomes. (PubMed, J Clin Neurol)
    Only ER expression was associated with the overall survival time when other confounding factors such as smoking status and treatment type were considered. A smoking history was associated with shorter survival, while eribulin was associated with survival prolongation.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    Perjeta (pertuzumab) • capecitabine • eribulin mesylate
    1m
    ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, ALX Oncology Inc.
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • gemcitabine • paclitaxel • capecitabine • eribulin mesylate • vinorelbine tartrate • evorpacept (ALX148)
    1m
    OptiTROP Breast02: Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P3, N=376, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    gemcitabine • capecitabine • eribulin mesylate • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)
    1m
    Long-term survival with eribulin in an elderly patient with inoperable retroperitoneal well-differentiated liposarcoma: a case report and literature review. (PubMed, Front Oncol)
    Due to age, comorbidities, and unresectable disease, first-line therapy with anlotinib was initiated. This case suggests that eribulin may provide durable disease control and is a well-tolerated therapeutic option for elderly patients with inoperable retroperitoneal WDLPS, providing preliminary evidence for its potential to achieve long-term tumor stability and maintain quality of life in this vulnerable population. Multidisciplinary assessment and individualized treatment strategies remain essential in optimizing outcomes.
    Journal
    |
    MDM2 (E3 ubiquitin protein ligase)
    |
    Focus V (anlotinib) • eribulin mesylate
    1m
    MEDOPP0776: PHASE?IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN HER2-POSITIVE ADVANCED BREAST CANCER (The JAZMINE Study) (2025-524613-89-00)
    P1/2, N=129, Not yet recruiting, Medica Scientia Innovation Research S.L.
    New P1/2 trial
    |
    HER-2 positive • HER-2 amplification
    |
    capecitabine • eribulin mesylate • Tukysa (tucatinib) • dexamethasone • Ziihera (zanidatamab-hrii)
    1m
    Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=792, Recruiting, Hoffmann-La Roche | N=56 --> 792
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • eribulin mesylate • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Actemra IV (tocilizumab) • atirmociclib (PF-07220060) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)